ImmunoCellular (IMUC) is a clinical stage biotech company focused on the research and development of innovative cancer therapeutics. The company's lead drug candidate ICT-107 is a next-generation cancer vaccine targeting cancer stem cells to prevent recurrence.
ICT-107 has demonstrated the best clinical data for glioblastoma so far and is under a Phase II trial. ICT-107 holds a high promise for glioblastoma and has potential for other cancers. IMUC also has a pipeline based on its off-the-shelf peptide vaccine technology and monoclonal antibody technology, which ensures sustainable growth for the company.
IMUC is heading in the right direction and poised to deliver shareholder value. We think at this time IMUC should be valued between $200 and $300 million in market cap. Our $7.00 per share price target represents a market cap of $266 million.
More From Zacks.com